albertbourla
Albert Bourla, chief executive officer of Pfizer, estimates $54 billion in sales from its Covid-19 vaccine and new treatment pill Paxlovid in 2022. The COVID-19 shots are expected to generate $32 billion and Paxlovid is estimated to bring in $22 billion. Paxlovid, a new antiviral coronavirus treatment pill, received authorization from the FDA in December. This pill has already contributed $76 million in U.S sales. Pfizer expects to produce six million courses of Paxlovid for the first quarter and 120 million by the end of the year. According to Pfizer, Paxlovid reduces the risk of hospitalizat...
uPolitics.com
Pfizer and BioNTech will seek emergency authorization from Food and Drug Administration (FDA) for their COVID-19 vaccine to be administered for children under 5 in November, Pfizer’s Chief Financial Officer Frank D’Amelio said at an industry conference on Tuesday. Pfizer has also previously revealed that the company is preparing to file for emergency use authorization for children ages 5 to 11 by October. Pfizer’s CEO Albert Bourla also said that the company plans to release clinical trial data on its COVID-19 vaccine’s efficacy for children under five as early as the end of October. “Then, it...
uPolitics.com
Pfizer CEO Albert Bourla said that recipients of his company’s COVID-19 vaccination, as well as those of similar make-up like the Moderna vaccine, will “likely” require a third dose for increased immunity against the virus and its variants. Bourla also indicated people may need annual doses of the vaccine, similar to a flu shot. “A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual re-vaccination, but all of that needs to be confirmed. And again, the variants will play a key role,” Bourla said i...
uPolitics.com
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら